SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-04-25 EDT			5-day change	1st Jan Change
23.19 ^CNY	+1.35%		+3.02%	-7.35%

04-24	Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	MT
04-18	China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	04-24
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	04-08
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	03-25
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	03-14
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	03-08
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	03-07
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	03-04
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	02-29
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	02-20
Yuyuan Tourist Mart CFO Steps Down	02-05
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug	01-25
China Grants Clinical Trial Approval for Fosun Pharma Unit's Bronchiectasis Tablets	01-15
Fosun Pharma Board Approves Unlocking, Vesting of Shares	01-10
Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Mutual Supply Framework Agreement with Fosun International Limited	12-15
Chinese Drug Regulator Accepts Fosun Pharma Subsidiary's Application for Diet Supplement	12-11
Fosun Pharmaceutical's Unit Scraps Clinical Trial on ORIN1001 Tablet	12-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Other languages

Filters